FDA Approval Alert: The Need-to-Know | Datopotamab Deruxtecan in Metastatic HR+/HER2– Breast Cancer

In January 2025, the FDA approved datopotamab deruxtecan as a therapy for adults with previously treated unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

Data from the TROPION-Breast01 trial support the FDA approval of datopotamab deruxtecan for those with metastatic HR–positive, HER2-negative breast cancer.
FDA Approves Dato-DXd in Metastatic HR+/HER2– Breast Cancer
Article
Jan 17, 2025 6:46 PM
Data from the TROPION-Breast01 trial support the FDA approval of datopotamab deruxtecan for those with metastatic HR–positive, HER2-negative breast cancer.